lasmiditan sold brand name reyvow medication used acute active shortterm treatment migraine without aura sensory phenomenon visual disturbance useful taken common side effects include sleepiness dizziness tiredness lasmiditan approved united states october became available february developed eli us food drug administration fda considers firstinclass lasmiditan serotonin receptor agonist like unsuccessful selectively binds receptor subtype number triptans shown act subtype well affinity made responsible antimigraine lack affinity receptors might result fewer side effects related vasoconstriction compared triptans susceptible people ischemic heart disease raynauds phenomenon myocardial although review found sideeffects rarely occur people taking risk driving impairment taking lasmiditan people advised drive operate machinery least eight hours taking lasmiditan even feel well enough people follow advice advised take lasmiditan drug causes central nervous system cns depression including dizziness sedation used caution taken combination alcohol cns lasmiditan discovered eli lilly company relicensed colucid pharmaceuticals colucid bought eli lilly allow eli lilly reacquire drugs intellectual drug protected patents phase ii clinical trials dose finding purposes completed intravenous early oral eli lilly submitted new drug application us food drug administration fda november three phase iii clinical trials completed spartan trial compared placebo mg samurai compared placebo mg doses lasmiditan gladiator openlabel study compared mg doses lasmiditan subjects received drug part prior topline results spartan trial showed drug induced met primary secondary endpoints trial primary result showed statistically significant improvement pain relief relative placebo hours first dose secondary result showed statistically significantly greater percentage subjects free bothersome symptom mbs compared placebo two hours following first fda approved lasmiditan primarily based data two clinical trials trial trial subjects migraine headaches without trials conducted sites united states united kingdom fda approved drug october placed schedule v january june committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending granting marketing authorization medicinal product rayvow intended treatment applicant medicinal product eli lilly nederland rayvow approved medical use european union august lasmiditan approved use canada drug sponsor canada eli lilly canada inc filed new drug submission february cancelled submission final decision issued health canada health canada completed review submission find deficiencies data packages provided submission however health canada eli lilly could come agreement interpretation cardiovascular data would worded product monograph drug sponsor cancelled submission january health canada issued final httpsenwikipediaorgwikilasmiditan